Trial Profile
BETAPREDICT - MS Patients Treated With BETAferon: PREDICTors of Treatment Adherence
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BETAPREDICT
- Sponsors Bayer
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.
- 05 Nov 2019 Planned primary completion date changed from 30 Sep 2019 to 29 Nov 2019.
- 04 Jul 2019 Planned End Date changed from 30 Sep 2019 to 31 Dec 2019.